Physician profile
Mckenzie Tucker
NPI 1215596036
$3,399.95
in general payments reported to CMS, 2019-2025
32 companies · $1,153 in 2025
The $1,153 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.86 · 2021: $12.21 · 2022: $108 · 2023: $771 · 2024: $1,299 · 2025: $1,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,195 · Education: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,194.84 |
| Education | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $891.05 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $316.42 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $312.82 | 2024-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $246.60 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $185.40 | 2022-2024 | Jardiance, Mounjaro, Emgality |
| Otsuka America Pharmaceutical, INC. | $158.51 | 2023-2025 | Rexulti, Abilify Maintena |
| Amgen INC. | $156.09 | 2023-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.91 | 2023-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $114.65 | 2024-2025 | Caplyta |
| Lundbeck LLC | $89.84 | 2023-2025 | Rexulti, Vyepti |
| Teva Pharmaceuticals USA, INC. | $76.96 | 2023-2024 | Austedo Xr |
| Glaxosmithkline, LLC. | $75.40 | 2019-2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.32 | 2023-2024 | Xifaxan |
| Exact Sciences Corporation | $63.25 | 2023-2025 | Cologuard Collection Kit |
| Alkermes, INC. | $54.83 | 2025 | Lybalvi |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $46.17 | 2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $45.67 | 2023-2025 | Eliquis |
| Eisai INC. | $44.93 | 2024 | |
| Axsome Therapeutics, INC. | $37.17 | 2023-2024 | Auvelity |
| Neurocrine Biosciences, INC. | $36.17 | 2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $34.07 | 2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $32.67 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.92 | 2022 | |
| Dexcom, INC. | $22.36 | 2023 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $20.62 | 2024 | Veozah |
| Ibsa Pharma INC. | $20.56 | 2025 | Licart, Flector, Tirosint |
| Vanda Pharmaceuticals INC. | $19.89 | 2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $19.19 | 2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $17.35 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.25 | 2023 | |
| Esperion Therapeutics, INC. | $15.81 | 2025 | Nexletol |
| Endogastric Solutions, INC | $7.10 | 2024 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mckenzie Tucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.